Open AccessWhole-body and single-photon emission computed tomography/computed tomography postpeptide receptor alpha radionuclide therapy images of actinium 225-tetraazacyclododecanetetraacetic Acid–Octreotide as a primary modality of treatment in a patient with advanced rectal neuroendocrine tumor with metastases
Author(s) -
Koramadai Karuppusamy Kamaleshwaran,
Suneelkumar Malipedda,
Raghunathan Madhusairam,
Edathuruthy Kalarikal Radhakrishnan,
Soundararajan Arunpandiyan,
Vasumathi Jayaraj Arnold
Publication year - 2020
Publication title -
indian journal of nuclear medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.261
H-Index - 13
eISSN - 0972-3919
pISSN - 0974-0244
DOI - 10.4103/ijnm.ijnm_58_20
Subject(s) - medicine , radionuclide therapy , neuroendocrine tumors , somatostatin receptor , octreotide , nuclear medicine , single photon emission computed tomography , radiology , emission computed tomography , computed tomography , positron emission tomography computed tomography , pet ct , positron emission tomography , somatostatin
Somatostatin receptor-targeted alpha radionuclide therapies have been introduced including actinium-225 labeled tetraazacyclododecanetetraacetic acid-octreotide (Ac-225 DOTATATE) for advanced metastatic neuroendocrine tumors (NET). Very limited data are available on the posttherapy imaging using Ac-225 DOTATATE therapy in metastatic NET. We present Ac-225 single-photon emission computed tomography/computed tomography images of a 72-year-old patient diagnosed as a case of advanced rectal NET treated primarily with Ac-225 DOTATATE.